← Leaderboards
Chenglong Li
Research Inst Nationwide Children'S Hosp
$3,890,740
Attributed
$7,917,917
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,917,917 · 8
By mechanism
R01$5,590,291 · 3
R21$1,280,559 · 3
T32$847,068 · 1
R56$199,999 · 1
Top collaborators
- Jiaoti Huang6 shared
- Jiayuh Lin6 shared
- Chang-Deng Hu5 shared
- Yuhong Yang4 shared
- Dennis Brian Mckay3 shared
- Robert Alan Baiocchi2 shared
- Lina Cui1 shared
- Yang Yang1 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Loren Eugene Wold$6,187,033
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistClinical TrialsBasePublic Health RelevanceSignal TransductionDrug KineticsMolecularLeadTissuesPathway InteractionsIn VivoStructurePharmaceutical PreparationsSmall MoleculeCellsToxic EffectPlayMediatingFutureEffective TherapyGenerationsOralIn VitroApoptosis
Grant awards (27)
AI-directed discovery of heparanase inhibitors$199,999
R56 · FY2024 · DK
Chemistry-Biology Interface Training Program at the University of Florida$169,715
T32 · FY2024 · GM · contact PI
Chemistry-Biology Interface Training Program at the University of Florida$179,494
T32 · FY2023 · GM · contact PI
Chemistry-Biology Interface Training Program at the University of Florida$175,425
T32 · FY2022 · GM · contact PI
Role and targeting of PRMT5 in prostate cancer$504,707
R01 · FY2021 · CA
Role and targeting of PRMT5 in prostate cancer$375,488
R01 · FY2021 · CA
Chemistry-Biology Interface Training Program at the University of Florida$162,332
T32 · FY2021 · GM · contact PI
Role and targeting of PRMT5 in prostate cancer$508,108
R01 · FY2020 · CA
A novel STAT3-selective inhibitor for medulloblastoma therapy$335,740
R01 · FY2020 · NS
Chemistry-Biology Interface Training Program at the University of Florida$160,102
T32 · FY2020 · GM · contact PI
Role and targeting of PRMT5 in prostate cancer$497,903
R01 · FY2019 · CA
A novel STAT3-selective inhibitor for medulloblastoma therapy$339,473
R01 · FY2019 · NS
Role and targeting of PRMT5 in prostate cancer$516,741
R01 · FY2018 · CA
Role and targeting of PRMT5 in prostate cancer$547,569
R01 · FY2017 · CA
Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy$342,568
R01 · FY2017 · NS · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$339,684
R01 · FY2017 · NS
Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy$330,037
R01 · FY2016 · NS · contact PI
Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy$140,524
R01 · FY2016 · NS · contact PI
Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy$471,114
R01 · FY2015 · NS · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$340,635
R01 · FY2015 · NS
Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas$221,022
R21 · FY2011 · NS
Novel lead molecule optimization targeting nicotinic receptor subtypes$268,736
R21 · FY2010 · DA
Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas$187,501
R21 · FY2010 · NS
Target Stat3 in pancreatic cancer using novel small molecule inhibitors$161,040
R21 · FY2010 · CA
Novel lead molecule optimization targeting nicotinic receptor subtypes$10,675
R21 · FY2010 · DA
Novel lead molecule optimization targeting nicotinic receptor subtypes$228,750
R21 · FY2009 · DA
Target Stat3 in pancreatic cancer using novel small molecule inhibitors$202,835
R21 · FY2009 · CA